Business Context and Reporting Period
This Form 8-K filing by DarioHealth Corp. (DRIO) reports a material definitive agreement and unregistered sales of equity securities. The report date is December 3, 2019, covering events that occurred on November 27, 2019.
Key Financial Metrics and Transaction Details
The Company completed an initial closing of a private placement offering with the following financial terms:
- Gross Proceeds: $13.56 million.
- Securities Issued: 8,361 shares of Series A Convertible Preferred Stock and 5,200 shares of Series A-1 Convertible Preferred Stock.
- Purchase Price: $1,000 per share for both Series A and Series A-1 Preferred Stock.
- Placement Agent Fees: $1,056,100 in cash fees and $406,830 in non-accountable expense allowances.
- Placement Agent Warrants: Warrants to purchase 485,688 shares of Common Stock at an exercise price of $4.05 per share.
The filing does not provide specific revenue, profit, cash flow, or debt metrics for the Company's ongoing operations.
Material Changes and Capital Structure
The Company amended its capital structure by filing Certificates of Designation for new preferred stock classes:
- Series A Preferred Stock: Authorized 25,000 shares; issued 8,361 shares. These shares carry voting rights on an as-converted basis and are entitled to dividends in the form of Common Stock (10% at 12 months, 15% at 24 months, and 20% at 36 months).
- Series A-1 Preferred Stock: Authorized 12,500 shares; issued 5,200 shares. These shares do not possess voting rights.
- Conversion Terms: Both series convert to Common Stock at an initial price of $4.05 per share. Automatic conversion occurs upon approval by holders of 50.1% of Series A or on the 36-month anniversary of the Effective Date.
- Liquidation Preference: Holders are entitled to receive the Stated Value ($1,000) plus accrued dividends before any distribution to Common Stock holders.
Outlook, Risks, and Contingencies
Management Commentary and Agreements:
- Registration Rights: The Company agreed to file a registration statement for the resale of Common Stock issuable upon conversion within 60 days of the closing.
- Board Representation: The Placement Agent has the right to appoint one representative to the Board of Directors if at least $10 million is raised in the Offering.
- Right of First Refusal: The Placement Agent has a 12-month right of first refusal to act as lead or co-placement agent for future U.S. private placements.
Risks and Exemptions:
- The securities were sold pursuant to Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D, and Regulation S for non-U.S. investors.
- The securities are not registered and may not be sold in the United States absent registration or an exemption.
- The filing explicitly states that representations and warranties in the Subscription Agreements are not for the benefit of the public and should not be relied upon for factual information about the Company's current state of affairs.
Investor Verification Checklist
- Verify the total amount raised in the Offering to confirm if the $10 million threshold for Board representation by the Placement Agent was met.
- Review the full text of the Series A and Series A-1 Certificates of Designation (Exhibits 3.1 and 3.2) for specific beneficial ownership limitations on conversion.
- Confirm the filing of the registration statement for the resale of shares within the required 60-day window.
- Assess the dilution impact of the 485,688 Placement Agent Warrants and the future dividend issuances (10%, 15%, 20%) on existing Common Stock holders.
- Check subsequent filings for the final closing details and total aggregate proceeds if the initial closing was not the final tranche.